Over the past decade it has been all about titer, titer, titer in the biopharm industry as process development groups strove to reach "holy grail-type" production levels of 10 g/L or more (at least for MaBs).
Now, many groups in the industry have reached that level or even exceeded 10 g/L and have concluded that may be too much. There seems to be a consensus building in the industry that 5 g/L is fine from a COGs perspective and that gains above 5 g/L don't save that much in additional COGs and create more problems with protein quality.
GEN will present an educational webinar on September 27th and 28th entitled, "Impact of High Titer Process on Product Quality". Registration for the webinar is FREE.
Topics covered will include the following:
- Comparing cell-line productivity using a traditional fed-batch system versus high-density cell culture to express Fc-fusion proteins or antibodies
- Impact on aggregation, glycosylation, and in vitro activity resulting from high-density cell culture processes
- Increasing titer output without changing the genetic construct or process media
- Downsizing bioreactors while maintaining high yields of a biopharmaceutical product
- Reducing cost of goods and time to market
The event will be moderated by GEN Editor in Chief, John Sterling. Industry Panelists include: David Bienvenue, Assoc. Dir., VLST Corp., Wei-Kuang Chi, VP and Director, cGMP Biopharmaceutical Plant, Development Center for Biotechnology, Rolf Douwenga, VP, Global R&D, DSM Biologics
Posted by Bruce Lehr September 21st 2010.